Compare iShares Global Clean Energy ETF (ICLN) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs Novo Nordisk A/S — how do they compare? iShares Global Clean Energy ETF trades at $17.2 (market cap $2.27B), while Novo Nordisk A/S trades at $38.39 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 72.8× iShares Global Clean Energy ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while iShares Global Clean Energy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Clean Energy ETF for 87 Days and Novo Nordisk A/S for 116 Days on average.
| ICLN | NVO | |
|---|---|---|
Market Cap | $2.27B | $165.31B |
Volume | 6,845,064 | 11,432,838 |
52-Week High | $23.75 | $63.98 |
52-Week Low | $15.78 | $35.29 |
Typical Hold Time | 87 Days | 116 Days |
Sector | — | Health |
Enterprise Value | — | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $17.17, down 0.81% with bearish technical signals from moving averages. The ETF shows neutral momentum oscillators but faces significant volatility compared to traditional energy peers. Recent news highlights ICLN's 57.2% maximum drawdown and higher expense ratio of 0.38% versus fossil fuel ETFs, though geopolitical tensions are driving renewed interest in renewable energy infrastructure.
The clean energy sector faces competitive pressure from higher-yielding traditional energy ETFs, but long-term growth prospects remain supported by global energy transition trends. Key risks include expense ratio disadvantages and sector volatility, while potential catalysts include increased renewable adoption driven by geopolitical and environmental factors.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
